Saudi experts set the thresholds for spotting and treating fatty liver disease early.
Faisal Abaalkhail, Faisal M. Sanai, Khalid AlSwat, et al.
A 15-expert Delphi panel developed Saudi-specific consensus recommendations for detecting and managing metabolic dysfunction-associated steatotic liver disease (MASLD), the updated name for fatty liver disease. The panel set concrete fibrosis-risk thresholds using noninvasive tests such as FIB-4 and elastography to guide when patients need specialist referral, and recommended a stepped approach spanning lifestyle change, drugs such as GLP-1 agonists and SGLT2 inhibitors, and bariatric surgery for eligible non-cirrhotic patients. The result is a practical, risk-stratified care pathway tailored to Saudi Arabia's high burden of metabolic disease.
- The question: How should Saudi clinicians detect fatty liver disease, and decide who needs a specialist?
- The study: A panel of 15 experts used a modified Delphi process to adapt international standards for Saudi Arabia.
- The finding: They set concrete fibrosis-risk thresholds, using noninvasive tests like FIB-4 and elastography, to guide specialist referral.
- The nuance: Care then steps up from lifestyle change to GLP-1 agonists and SGLT2 inhibitors, and bariatric surgery for eligible patients.
Takeaway: a risk-stratified pathway, tailored to Saudi Arabia's high metabolic burden, tells you who to treat in clinic and who to refer.
Narrated (standard AI voice, not a cloned voice) with burned-in captions matching the narration word-for-word — safe to watch muted. Built from this article’s SGA Briefing only.
This links to the publisher’s open-access copy of record. A self-hosted PDF will appear here once one is on file.